The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy biotechnology company EsoBiotec for up to $1 billion, it said on Monday, ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” fourth quarter 2024 ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...